Pfizer ROA 2012-2026 | PFE
Current and historical return on assets (ROA) values for Pfizer (PFE) over the last 10 years. Return on assets can be defined as an indicator of how profitable a company is relative to its total assets. Calculated by dividing a company's operating earnings by its total assets.
| Pfizer ROA - Return on Assets Historical Data | |||
|---|---|---|---|
| Date | TTM Net Income | Total Assets | Return on Assets |
| 2026-03-31 | $7.49B | $103.71B | 7.22% |
| 2025-12-31 | $7.77B | $155.71B | 4.99% |
| 2025-09-30 | $9.83B | $209.06B | 4.70% |
| 2025-06-30 | $10.75B | $211.75B | 5.08% |
| 2025-03-31 | $7.88B | $214.27B | 3.68% |
| 2024-12-31 | $8.03B | $217.54B | 3.69% |
| 2024-09-30 | $4.25B | $220.82B | 1.93% |
| 2024-06-30 | $-2.60B | $219.70B | -1.18% |
| 2024-03-31 | $-0.31B | $220.70B | -0.14% |
| 2023-12-31 | $2.12B | $214.33B | 0.99% |
| 2023-09-30 | $10.48B | $207.00B | 5.06% |
| 2023-06-30 | $21.47B | $202.09B | 10.63% |
| 2023-03-31 | $29.05B | $195.87B | 14.83% |
| 2022-12-31 | $31.37B | $192.92B | 16.26% |
| 2022-09-30 | $29.77B | $188.99B | 15.75% |
| 2022-06-30 | $29.31B | $184.95B | 15.85% |
| 2022-03-31 | $24.97B | $178.61B | 13.98% |
| 2021-12-31 | $21.98B | $172.35B | 12.75% |
| 2021-09-30 | $19.43B | $165.54B | 11.74% |
| 2021-06-30 | $12.76B | $165.49B | 7.71% |
| 2021-03-31 | $10.68B | $167.49B | 6.38% |
| 2020-12-31 | $9.16B | $169.37B | 5.41% |
| 2020-09-30 | $7.73B | $172.71B | 4.48% |
| 2020-06-30 | $13.94B | $170.58B | 8.17% |
| 2020-03-31 | $15.50B | $165.14B | 9.38% |
| 2019-12-31 | $16.03B | $162.42B | 9.87% |
| 2019-09-30 | $16.22B | $160.37B | 10.11% |
| 2019-06-30 | $12.65B | $159.72B | 7.92% |
| 2019-03-31 | $11.48B | $161.92B | 7.09% |
| 2018-12-31 | $11.15B | $164.21B | 6.79% |
| 2018-09-30 | $23.82B | $167.31B | 14.24% |
| 2018-06-30 | $22.55B | $168.39B | 13.39% |
| 2018-03-31 | $21.75B | $169.28B | 12.85% |
| 2017-12-31 | $21.31B | $170.32B | 12.51% |
| 2017-09-30 | $9.81B | $170.28B | 5.76% |
| 2017-06-30 | $8.32B | $171.85B | 4.84% |
| 2017-03-31 | $7.30B | $172.37B | 4.23% |
| 2016-12-31 | $7.22B | $170.91B | 4.22% |
| 2016-09-30 | $6.27B | $169.85B | 3.69% |
| 2016-06-30 | $7.04B | $167.96B | 4.19% |
| 2016-03-31 | $7.62B | $165.51B | 4.61% |
| 2015-12-31 | $6.96B | $164.94B | 4.22% |
| 2015-09-30 | $8.36B | $164.99B | 5.07% |
| 2015-06-30 | $8.90B | $165.11B | 5.39% |
| 2015-03-31 | $9.18B | $168.05B | 5.46% |
| 2014-12-31 | $9.14B | $170.84B | 5.35% |
| 2014-09-30 | $10.48B | $171.97B | 6.09% |
| 2014-06-30 | $10.40B | $173.01B | 6.01% |
| 2014-03-31 | $21.58B | $174.69B | 12.35% |
| 2013-12-31 | $22.00B | $178.59B | 12.32% |
| 2013-09-30 | $25.75B | $182.01B | 14.15% |
| 2013-06-30 | $26.37B | $183.78B | 14.35% |
| 2013-03-31 | $15.53B | $184.66B | 8.41% |
| 2012-12-31 | $14.57B | $184.23B | 7.91% |
| 2012-09-30 | $9.69B | $184.78B | 5.25% |
| 2012-06-30 | $10.22B | $188.17B | 5.43% |
| 2012-03-31 | $9.58B | $191.43B | 5.00% |
| 2011-12-31 | $10.01B | $193.75B | 5.17% |
| 2011-09-30 | $11.46B | $195.50B | 5.86% |
| 2011-06-30 | $8.59B | $194.32B | 4.42% |
| 2011-03-31 | $8.45B | $193.11B | 4.38% |
| 2010-12-31 | $8.26B | $193.15B | 4.27% |
| 2010-09-30 | $6.13B | $197.64B | 3.10% |
| 2010-06-30 | $8.15B | $185.11B | 4.40% |
| 2010-03-31 | $7.93B | $172.17B | 4.61% |
| 2009-12-31 | $8.64B | $154.13B | 5.60% |
| 2009-09-30 | $8.13B | $128.68B | 6.32% |
| 2009-06-30 | $7.53B | $122.17B | 6.17% |
| 2009-03-31 | $8.05B | $116.46B | 6.91% |
| 2008-12-31 | $8.10B | $115.37B | 7.02% |
| 2008-09-30 | $10.56B | $116.40B | 9.07% |
| 2008-06-30 | $9.05B | $114.84B | 7.88% |
| 2008-03-31 | $7.54B | $113.31B | 6.65% |
| 2007-12-31 | $8.14B | $111.30B | 7.32% |
| 2007-09-30 | $14.87B | $111.37B | 13.35% |
| 2007-06-30 | $17.47B | $111.25B | 15.70% |
| 2007-03-31 | $18.62B | $111.54B | 16.69% |
| 2006-12-31 | $19.34B | $112.16B | 17.24% |
| 2006-09-30 | $12.62B | $112.52B | 11.22% |
| 2006-06-30 | $10.85B | $112.96B | 9.60% |
| 2006-03-31 | $11.90B | $113.15B | 10.51% |
| 2005-12-31 | $8.09B | $115.64B | 6.99% |
| 2005-09-30 | $8.18B | $117.17B | 6.98% |
| 2005-06-30 | $9.93B | $120.14B | 8.27% |
| 2005-03-31 | $9.33B | $122.05B | 7.65% |
| 2004-12-31 | $11.36B | $121.89B | 9.32% |
| 2004-09-30 | $9.14B | $120.31B | 7.59% |
| 2004-06-30 | $8.03B | $119.77B | 6.70% |
| 2004-03-31 | $1.58B | $120.85B | 1.30% |
| 2003-12-31 | $3.91B | $103.51B | 3.78% |
| 2003-09-30 | $6.17B | $85.90B | 7.18% |
| 2003-06-30 | $6.28B | $67.11B | 9.36% |
| 2003-03-31 | $11.83B | $46.68B | 25.34% |
| 2002-12-31 | $9.13B | $43.78B | 20.85% |
| 2002-09-30 | $8.23B | $41.98B | 19.60% |
| 2002-06-30 | $7.95B | $40.46B | 19.65% |
| 2002-03-31 | $7.82B | $39.05B | 20.03% |
| 2001-12-31 | $7.79B | $37.51B | 20.76% |
| 2001-09-30 | $7.25B | $36.10B | 20.09% |
| 2001-06-30 | $6.54B | $34.77B | 18.81% |
| 2001-03-31 | $5.86B | $33.55B | 17.47% |
| 2000-12-31 | $3.73B | $29.82B | 12.50% |
| 2000-09-30 | $3.26B | $26.58B | 12.27% |
| 2000-06-30 | $3.30B | $23.27B | 14.17% |
| 2000-03-31 | $2.86B | $20.17B | 14.16% |
| 1999-12-31 | $3.88B | $19.87B | 19.50% |
| 1999-09-30 | $3.63B | $19.30B | 18.82% |
| 1999-06-30 | $3.63B | $18.79B | 19.33% |
| 1999-03-31 | $3.55B | $18.00B | 19.72% |
| 1998-12-31 | $3.43B | $17.24B | 19.89% |
| 1998-09-30 | $3.28B | $16.49B | 19.86% |
| 1998-06-30 | $2.47B | $15.79B | 15.67% |
| 1998-03-31 | $2.30B | $15.59B | 14.77% |
| 1997-12-31 | $2.21B | $15.37B | 14.40% |
| 1997-09-30 | $2.16B | $15.20B | 14.20% |
| 1997-06-30 | $2.08B | $15.02B | 13.83% |
| 1997-03-31 | $2.01B | $14.49B | 13.90% |
| 1996-12-31 | $1.93B | $14.02B | 13.76% |
| 1996-09-30 | $1.84B | $13.54B | 13.57% |
| 1996-06-30 | $1.75B | $13.09B | 13.35% |
| 1996-03-31 | $1.67B | $12.92B | 12.92% |
| 1995-12-31 | $1.57B | $12.75B | 12.33% |
| 1995-09-30 | $1.50B | $12.35B | 12.11% |
| 1995-06-30 | $1.41B | $11.74B | 11.98% |
| 1995-03-31 | $1.35B | $11.03B | 12.22% |
| 1994-12-31 | $1.30B | $10.31B | 12.60% |
| 1994-09-30 | $1.25B | $9.87B | 12.71% |
| 1994-06-30 | $0.70B | $9.74B | 7.22% |
| 1994-03-31 | $0.70B | $9.72B | 7.20% |
| 1993-12-31 | $0.66B | $9.74B | 6.76% |
| 1993-09-30 | $0.65B | $9.80B | 6.61% |
| 1993-06-30 | $1.16B | $9.87B | 11.76% |
| 1993-03-31 | $1.13B | $9.75B | 11.55% |
| 1992-12-31 | $1.08B | $9.69B | 11.11% |
| 1992-09-30 | $0.80B | $9.70B | 8.23% |
| 1992-06-30 | $0.78B | $9.42B | 8.23% |
| 1992-03-31 | $0.73B | $9.23B | 7.95% |
| 1991-12-31 | $0.72B | $9.07B | 7.96% |
| 1991-09-30 | $0.88B | $8.93B | 9.82% |
| 1991-06-30 | $0.84B | $8.81B | 9.58% |
| 1991-03-31 | $0.82B | $8.62B | 9.46% |
| 1990-12-31 | $0.80B | $8.41B | 9.53% |
| 1990-09-30 | $0.73B | $8.23B | 8.91% |
| 1990-06-30 | $0.71B | $8.03B | 8.82% |
| 1990-03-31 | $0.69B | $7.92B | 8.76% |
| 1989-12-31 | $0.68B | $7.83B | 8.71% |
| 1989-09-30 | $0.74B | $7.66B | 9.63% |
| 1989-06-30 | $0.74B | $7.55B | 9.75% |
| 1989-03-31 | $0.81B | $7.43B | 10.94% |
| 1988-12-31 | $0.79B | $7.28B | 10.89% |
| 1988-09-30 | $0.79B | $7.10B | 11.09% |
| 1988-06-30 | $0.76B | $6.73B | 11.23% |
| 1988-03-31 | $0.72B | $6.36B | 11.31% |
| 1987-12-31 | $0.69B | $5.96B | 11.59% |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Large Cap Pharmaceutical | $153.074B | $62.579B |
| Pfizer Inc. is a research-based, global biopharmaceutical company. The company boasts a sustainable pipeline with multiple late-stage programs that can drive growth. Pfizer markets a wide range of drugs and vaccines. Its business comprises six business units - Oncology, Inflammation & Immunology, Rare Disease, Hospital, Vaccines and Internal Medicine. Pfizer spinned-off its Upjohn unit, its off-patent branded and generic established medicines business, and combined it with generic drugmaker Mylan to create a new generic pharmaceutical company called Viatris. The Consumer Healthcare (CHC) segment, an over-the-counter (OTC) medicines business, was merged with Glaxo's unit to form a new joint venture.?The Consumer Healthcare joint venture with Glaxo and the merger of Upjohn unit with Mylan has made Pfizer a smaller company with a diversified portfolio of innovative drugs and vaccines. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Eli Lilly (LLY) | United States | $887.629B | 38.81 |
| Johnson & Johnson (JNJ) | United States | $574.358B | 22.08 |
| AbbVie (ABBV) | United States | $367.673B | 20.79 |
| Roche Holding AG (RHHBY) | Switzerland | $318.782B | 0.00 |
| Merck (MRK) | United States | $299.893B | 13.54 |
| Novartis AG (NVS) | Switzerland | $293.951B | 17.16 |
| Novo Nordisk (NVO) | Denmark | $167.527B | 9.60 |
| Sanofi (SNY) | France | $114.048B | 10.56 |
| Bayer (BAYRY) | Germany | $46.178B | 8.70 |
| Innoviva (INVA) | United States | $1.760B | 5.88 |